METASTATIC COLORECTAL CANCER

This study is testing whether adding two new drugs (BNT314 and BNT327) to standard chemotherapy can help people with metastatic colorectal cancer that hasn't responded well to initial treatment. The trial will enroll about 482 participants across multiple sites. The goal is to se…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy in people whose colorectal cancer has spread. The goal is to see if the combination shrinks tumors and is safe. About 390 adults will take part at hospitals worldwide.

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests whether a combination of three drugs—adagrasib, cetuximab, and cemiplimab—can help control metastatic colorectal cancer in people whose tumors have a specific genetic change called KRAS G12C. About 31 adults whose cancer has not responded to at least one prior tr…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment based on specific biomarkers found in their tumor. The goal is to see if these per…

This early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ong…

This Phase 3 trial tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has progressed after prior therapies. About 1,020 participants will be randomly assigned to one of three treatment gro…

This Phase 3 study tests whether adding the targeted drug sotorasib and another drug called panitumumab to standard chemotherapy (FOLFIRI) works better than standard chemo alone (with or without bevacizumab) for people with metastatic colorectal cancer that has a specific KRAS G1…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This early-stage study is testing a new treatment for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the disease. About…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination can shrink tumors and improve …

This phase 3 trial is testing whether a new drug called amivantamab, combined with standard chemotherapy (FOLFIRI), can help people with advanced colorectal cancer live longer without their disease getting worse. The study includes 700 participants whose cancer has returned or sp…

This study tests two different chemotherapy combinations for people with metastatic colorectal cancer that has spread and needs a second treatment. About 280 adults will be randomly assigned to receive either FOLFIRI or irinotecan, with or without bevacizumab. The goal is to see …

This study is tracking how well a biosimilar drug called Elovie (a copy of bevacizumab) works for people with advanced colorectal cancer that cannot be removed by surgery. Researchers will follow 133 patients in Brazil who are receiving Elovie as their first treatment, measuring …

This study tests a drug called ivonescimab in 90 adults with advanced colorectal cancer that has already been treated. The drug is designed to help the immune system fight the cancer. Researchers want to see if it is safe and can control the disease.

This Phase 2a trial tests an experimental drug called RBS2418 in 150 adults with advanced, metastatic colorectal cancer that has worsened despite standard treatments. The drug is designed to help the immune system recognize and attack cancer cells. Participants will receive eithe…

This phase 2 trial is testing a new immunotherapy drug called volrustomig, combined with standard chemotherapy (FOLFIRI) and bevacizumab, in 120 people with metastatic colorectal cancer. The goal is to see if the combination is safe and helps control the cancer longer. Participan…

This study tests a new drug called JS212, which is designed to target two proteins on cancer cells (EGFR and HER3) and deliver a chemotherapy-like payload directly to them. It is being tested in combination with other standard cancer drugs in 80 adults with metastatic colorectal …

This study tests a new combination of drugs for people with advanced colorectal cancer that has stopped responding to initial treatment. About 30 adults aged 18-75 will receive a mix of chemotherapy and targeted therapy. The goal is to see if this approach can delay cancer growth…

This study compares a new experimental drug, RPH-030, to the approved drug Vectibix in people with metastatic colorectal cancer that has a specific gene type (wild-type RAS). About 180 participants will receive either RPH-030 or Vectibix along with standard chemotherapy (FOLFIRI)…

This study tests a two-part treatment for people with colorectal or non-small cell lung cancer that has spread to the liver and hasn't responded to standard therapies. The treatment combines a liver-directed procedure (TATE) that delivers a chemotherapy-like drug directly to the …

This early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have not responded to prior treatments. The goal is to find safe and effective doses. About 128 participants wi…

This study is testing whether a combination of three drugs—liposomal irinotecan, TAS102, and bevacizumab—can help people with metastatic colorectal cancer that has not responded to prior treatments. About 50 adults with mismatch repair proficient tumors will receive the drugs in …

This phase 2 trial is testing enfortumab vedotin, a drug that delivers chemotherapy directly to cancer cells, in 40 adults with advanced colorectal or liver cancer that has worsened after standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will…

This study tests a new way of giving three chemotherapy drugs (TAS-102, oxaliplatin, and irinotecan) along with bevacizumab to people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this approach can control the cancer and…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This early-phase trial tests the safety and best dose of a drug called ulixertinib when given with cetuximab and/or encorafenib. It is for people with advanced colorectal cancer that has spread and who have already tried treatments targeting EGFR or BRAF. The goal is to find a do…

This study tests a new drug called EMB-01 in people with advanced colorectal cancer that has come back or spread. The goal is to see if different dosing schedules can shrink tumors and how safe the drug is. About 54 adults will take part, and they will be assigned to receive EMB-…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This early-phase trial is testing a combination of five chemotherapy drugs (FLIRT plus bevacizumab) as a first treatment for people with a specific type of metastatic colorectal cancer that has spread. The cancer must have a silenced MGMT gene and be microsatellite stable. The st…

This study tests a new drug called YL242, given alone or with other treatments, for adults with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 participants will take part in this early-phase t…

This phase 2 trial tests whether adding an immunotherapy drug (envafolimab) and a stronger chemotherapy mix (mFOLFOXIRI) to the standard treatment (cetuximab plus mFOLFOX6) can better control advanced left-sided colorectal cancer that has spread. About 198 people with a specific …

This Phase II trial tests whether combining fruquintinib (a targeted therapy) with tislelizumab (an immunotherapy) can help people with a specific type of advanced colorectal cancer that has not spread to the liver. The study will enroll 140 participants whose tumors are microsat…

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study looks at people with advanced colorectal cancer whose tumor tissue shows no RAS/BRAF mutation, but a liquid biopsy (blood test) finds a RAS mutation. It compares two standard drug combos (FOLFIRI plus either cetuximab or bevacizumab) to see which works better at stoppi…

This study tests a new type of PET/CT scan that uses a radioactive tracer called FAPI to detect an aggressive form of colorectal cancer known as CMS4. The CMS4 subtype is linked to worse outcomes and may not respond well to standard chemotherapy. Researchers will scan 45 patients…

This phase 3 trial tests whether Nuvastatic 300mg, a herbal supplement, can reduce cancer-related fatigue in adults with metastatic colorectal cancer who are receiving standard chemotherapy. About 250 participants will take either Nuvastatic or a placebo three times daily for abo…

This study looks at why a specific type of advanced colorectal cancer (with a BRAF V600E mutation) becomes resistant to standard targeted therapy. Researchers will collect tumor tissue, blood, and stool samples from 30 patients before treatment and when the disease progresses. Th…

This study aims to create a mindfulness program designed for couples where one partner has metastatic colorectal cancer. Researchers will interview patients, their partners, and clinicians to understand their needs and preferences for such a program. The goal is to design a progr…

This study looks at gut bacteria in 300 people with colorectal cancer to see if certain bacteria are linked to cancer spread. Researchers will compare stool and tissue samples from patients whose cancer has spread versus those whose cancer has not. The goal is to find bacterial p…

This study is collecting medical information and blood samples from 400 people with metastatic colorectal cancer that has a specific genetic change called BRAFV600E. The goal is to learn more about how this cancer is treated in everyday practice and what outcomes patients experie…

This study observes 1000 patients with metastatic colorectal cancer whose first chemotherapy stopped working. Researchers will track which second-line treatments doctors choose and how long patients live or stay cancer-free. The goal is to understand real-world treatment patterns…